Skip to main content
Log in

Chronic myeloproliferative neoplasms

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses

  • Brief Communication
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065–72.

    Article  PubMed  CAS  Google Scholar 

  2. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418–24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101:3294–301.

    Article  PubMed  CAS  Google Scholar 

  4. King KY, Matatall KA, Shen CC, Goodell MA, Swierczek SI, Prchal JT. Comparative long-term effects of interferon alpha and hydroxyurea on human hematopoietic progenitor cells. Exp Hematol. 2015;43:912–8 e2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Pourcelot E, Trocme C, Mondet J, Bailly S, Toussaint B, Mossuz P. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42:360–8.

    Article  PubMed  CAS  Google Scholar 

  6. Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL, Pardanani A, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87:1003–5.

    Article  PubMed  CAS  Google Scholar 

  7. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118:6392–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Hayes CN, Imamura M, Aikata H, Chayama K. Genetics of IL28B and HCV--response to infection and treatment. Nat Rev Gastroenterol Hepatol. 2012;9:406–17.

    Article  PubMed  CAS  Google Scholar 

  9. Lindgren M, Pettersson H, Westin J, Lindh M, Johansson P, Andreasson B. Influence of interferon-α treatment outcome in polycythemia vera and essential thrombocythemia by genetic polymorphism in IL28B. J Hematol Malig. 2012;2:18–25.

    Google Scholar 

  10. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35:32–8.

    Article  PubMed  CAS  Google Scholar 

  11. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90.

    Article  PubMed  CAS  Google Scholar 

  12. Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol. 2008;36:1480–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Bruchova H, Yoon D, Agarwal AM, Swierczek S, Prchal JT. Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation. Blood Cells Mol Dis. 2009;43:81–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal JT. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol. 2007;35:587–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Chen Y, Zou Z, Wu Z, Zhao Z, Luo X, Xie C, et al. TNF-alpha-induced programmed cell death in the pathogenesis of acquired aplastic anemia. Expert Rev Hematol. 2015;8:515–26.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to Dr. Bruce Beutler for advice to use TNFα inhibitor, adalimumab.

Author contributions

JP conceived and designed this study; TT collected and analyzed the data and drafted the manuscript; SS conceived TNFα studies and with SJK and JS performed the molecular analyses; KK isolated CD34+ cells from the marrows, MS and NH analyzed cytokines, KH and SL secured IRB compliance. All authors approved the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Josef T. Prchal.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

These authors contributed equally: Tsewang Tashi, Sabina Swierczek, Soo Jin Kim.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tashi, T., Swierczek, S., Kim, S.J. et al. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. Leukemia 32, 1830–1833 (2018). https://doi.org/10.1038/s41375-018-0080-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0080-6

  • Springer Nature Limited

This article is cited by

Navigation